GlassScriptPhysician profile
Farouk Y Khan
NPI 1427021948
$804.95
in general payments reported to CMS, 2019-2025
10 companies · $22.99 in 2025
The $22.99 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $156 · 2021: $99.11 · 2022: $134 · 2023: $104 · 2024: $38.56 · 2025: $22.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $239.44 | 2019-2021 | |
| Biogen, INC. | $150.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $123.28 | 2022-2024 | Austedo, Austedo Xr |
| Abbvie INC. | $86.42 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $77.51 | 2021-2025 | Invega Sustenna |
| Sk Life Science, INC. | $63.90 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $20.11 | 2024 | Rexulti, Abilify Maintena |
| Brainsway USA INC | $19.22 | 2019 | |
| Merck Sharp & Dohme LLC | $12.72 | 2021 | |
| Eisai INC. | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farouk Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.